Drs. Thomas Patterson, chief of the Division of Infectious Diseases, and Jason Bowling, Infectious Diseases, explained the implications of the FDA fast-tracking emergency authorization of the new anti-viral drug, remdesivir, as the new standard of care for hospitalized COVID-19 patients.
